Evolus (EOLS) Long-Term Deferred Tax (2022 - 2023)
Evolus (EOLS) posted Long-Term Deferred Tax of $83.3 million for Q4 2023, up 574.53% on a QoQ basis from $12.3 million in Q4 2022, and up 574.53% year-over-year from $12.3 million in Q4 2022.
Evolus (EOLS) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Evolus' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $83.3 million for Q4 2023.
- Quarterly Long-Term Deferred Tax rose 574.53% year-over-year to $83.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $83.3 million (up 574.53% YoY) and the FY2023 annual result came in at $83.3 million, up 574.53% from the prior year.
- Long-Term Deferred Tax was $83.3 million for Q4 2023 at Evolus, up from $12.3 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $83.3 million in Q4 2023 and bottomed at $12.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 83.26 Mn |
| Dec 31, 2022 | 12.34 Mn |